A LinkedIn post from Orasis Pharmaceuticals highlights the company’s support of Presbyopia Awareness Month by featuring prescriber Dámaris Raymondi, O.D., FAAO. The post points to an “exciting new category” of presbyopia eye drops and directs readers to safety information and educational resources on treatment benefits and risks.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The content suggests Orasis is emphasizing clinical engagement and real‑world prescriber perspectives to build credibility for its presbyopia therapy. For investors, this focus on awareness and education may indicate an ongoing commercial push to expand adoption in the large U.S. presbyopia population, with potential implications for prescription volume and long‑term market positioning in vision care therapeutics.